EP Patent

EP4045076A1 — Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease

Assigned to Board Of Regents Of Theuniversity Of Nebraska · Expires 2022-08-24 · 4y expired

What this patent protects

The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure c…

USPTO Abstract

The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP4045076A1
Jurisdiction
EP
Classification
—
Expires
2022-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Board Of Regents Of Theuniversity Of Nebraska
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.